RILPIVIRINE

RILPIVIRINE was reported 7138 times

RILPIVIRINE is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 HLA-B*5701 ASSAY POSITIVE 2 0.4000
1 PROCTITIS CHLAMYDIAL 4 0.3636
2 PRODUCT USE IN UNAPPROVED THERAPEUTIC ENVIRONMENT 272 0.3112
3 LYMPHOMA AIDS RELATED 2 0.2500
4 PERINATAL HIV INFECTION 3 0.2143
5 BLOOD HIV RNA BELOW ASSAY LIMIT 3 0.2000
6 JANEWAY LESION 2 0.1818
7 GALLBLADDER AGENESIS 2 0.1818
8 CONGENITAL CYTOMEGALOVIRUS INFECTION 27 0.1588
9 FLOPPY EYELID SYNDROME 5 0.1429
10 DISSEMINATED MYCOBACTERIUM AVIUM COMPLEX INFECTION 28 0.1267
11 BLOOD HIV RNA INCREASED 223 0.1229
12 VIRAL LOAD INCREASED 465 0.1197
13 OROPHARYNGEAL GONOCOCCAL INFECTION 3 0.1111
14 SINGLE COMPONENT OF A TWO-COMPONENT PRODUCT ADMINISTERED 10 0.1111
15 HEPATITIS SYPHILITIC 2 0.1111
16 INJECTION SITE PANNICULITIS 2 0.1053
17 VIRAL LOAD ABNORMAL 17 0.0971
18 HUMAN IMMUNODEFICIENCY VIRUS TRANSMISSION 26 0.0935
19 CD4 LYMPHOCYTE PERCENTAGE DECREASED 4 0.0909
20 BLOOD CATECHOLAMINES ABNORMAL 2 0.0909
21 VIROLOGIC FAILURE 445 0.0827
22 ACUTE HEPATITIS B 24 0.0723
23 VIRAL MUTATION IDENTIFIED 244 0.0662
24 INJECTION SITE MUSCLE ATROPHY 2 0.0625
25 CHRONIC ACTINIC DERMATITIS 2 0.0571
26 HIV VIRAEMIA 11 0.0524
27 ADMINISTRATION SITE NECROSIS 2 0.0500
28 CRYPTOSPORIDIOSIS INFECTION 26 0.0495
29 AIDS RELATED COMPLICATION 3 0.0462
30 MONKEYPOX 12 0.0435
31 CONGENITAL AORTIC VALVE INCOMPETENCE 6 0.0432
32 HEPATITIS B ANTIGEN POSITIVE 2 0.0417
33 PATHOGEN RESISTANCE 352 0.0386
34 SYPHILIS 27 0.0371
35 ADMINISTRATION SITE WARMTH 3 0.0366
36 INJECTED LIMB MOBILITY DECREASED 5 0.0350
37 CD4 LYMPHOCYTES INCREASED 8 0.0343
38 DRUG RESISTANCE MUTATION 6 0.0337
39 ADMINISTRATION SITE INDURATION 3 0.0333
40 ADMINISTRATION SITE DISCOMFORT 6 0.0317
41 GASTRIC ADENOMA 2 0.0303
42 ABDOMINAL LYMPHADENOPATHY 26 0.0300
43 INJECTION SITE GRANULOMA 7 0.0295
44 ENCAPSULATION REACTION 3 0.0291
45 VIRAL LOAD 5 0.0289
46 CSF VIRUS IDENTIFIED 2 0.0286
47 FEMORAL NERVE INJURY 2 0.0278
48 ANTIVIRAL DRUG LEVEL ABOVE THERAPEUTIC 2 0.0267
49 MELANODERMA 5 0.0260
50 CONGENITAL TRICUSPID VALVE INCOMPETENCE 5 0.0250
51 CD8 LYMPHOCYTES DECREASED 5 0.0249
52 VENTRICULAR HYPOPLASIA 6 0.0240
53 COUGH VARIANT ASTHMA 2 0.0238
54 INJECTION SITE PLAQUE 5 0.0238
55 HEPATITIS B REACTIVATION 75 0.0236
56 ATRIOVENTRICULAR SEPTAL DEFECT 11 0.0234
57 ADMINISTRATION SITE OEDEMA 2 0.0233
58 VIRAEMIA 32 0.0231
59 TOXIC CARDIOMYOPATHY 5 0.0223
60 CSF HIV ESCAPE SYNDROME 3 0.0217
61 BETA 2 MICROGLOBULIN URINE INCREASED 3 0.0210
62 VIRAL LOAD DECREASED 3 0.0205
63 NASAL VESTIBULITIS 2 0.0200
64 PRIMARY HYPOGONADISM 3 0.0191
65 CD4 LYMPHOCYTES DECREASED 40 0.0187
66 SUBSTANCE USE 29 0.0186
67 BLOOD TRIGLYCERIDES ABNORMAL 16 0.0183
68 TOXIC NEUROPATHY 7 0.0178
69 INJECTION SITE FIBROSIS 2 0.0171
70 HAEMORRHOIDS THROMBOSED 5 0.0166
71 LARYNGEAL NEOPLASM 2 0.0164
72 BENIGN ETHNIC NEUTROPENIA 2 0.0156
73 INJECTION SITE MOVEMENT IMPAIRMENT 2 0.0156
74 INJECTION SITE ABSCESS 38 0.0153
75 HEPATITIS B 92 0.0153
76 CHOLESTASIS OF PREGNANCY 7 0.0152
77 QUARANTINE 3 0.0146
78 INJECTION SITE NODULE 158 0.0143
79 ABSCESS STERILE 2 0.0135
80 EYE PARAESTHESIA 2 0.0127
81 ADNEXA UTERI CYST 2 0.0123
82 MOTOR NEURONE DISEASE 6 0.0123
83 LOCAL REACTION 9 0.0121
84 HELLP SYNDROME 7 0.0114
85 GONORRHOEA 3 0.0111
86 MYOSCLEROSIS 4 0.0108
87 HEPATITIS A 9 0.0106
88 INJECTION SITE PUSTULE 4 0.0105
89 PRODUCT ADMINISTERED BY WRONG PERSON 4 0.0105
90 OPHTHALMIC HERPES SIMPLEX 6 0.0104
91 INJECTION SITE CYST 3 0.0102
92 INJECTION SITE DISCHARGE 54 0.0100
93 DISEASE RISK FACTOR 4 0.0100
94 LIPODYSTROPHY ACQUIRED 21 0.0099
95 CD4 LYMPHOCYTES ABNORMAL 2 0.0095
96 PAPILLOMA 3 0.0095
97 ANGIOMYOLIPOMA 2 0.0093
98 EXTRAOCULAR MUSCLE DISORDER 3 0.0093
99 CHLAMYDIAL INFECTION 7 0.0093
100 SEXUALLY TRANSMITTED DISEASE 4 0.0092
101 RENAL TUBULAR DYSFUNCTION 5 0.0088
102 INJECTION SITE OEDEMA 15 0.0087
103 ADMINISTRATION SITE PAIN 10 0.0087
104 MALABSORPTION FROM ADMINISTRATION SITE 2 0.0086
105 MUSCLE HYPERTROPHY 3 0.0085
106 HYPOTHALAMIC PITUITARY ADRENAL AXIS SUPPRESSION 3 0.0084
107 GRANULOMATOUS DERMATITIS 2 0.0082
108 GENE MUTATION 16 0.0081
109 BODY DYSMORPHIC DISORDER 3 0.0080
110 FACIAL WASTING 2 0.0074
111 HEPATITIS B DNA INCREASED 5 0.0074
112 MONOCLONAL IMMUNOGLOBULIN INCREASED 2 0.0070
113 PRODUCT COMPLAINT 177 0.0070
114 HEPATITIS B SURFACE ANTIBODY POSITIVE 2 0.0068
115 INJECTION SITE DISCOMFORT 72 0.0068
116 INDURATION 12 0.0067
117 BODY MASS INDEX DECREASED 3 0.0065
118 MALABSORPTION FROM INJECTION SITE 2 0.0065
119 MENINGOCOCCAL INFECTION 2 0.0063
120 GLOMERULAR FILTRATION RATE INCREASED 5 0.0061
121 INJECTION SITE NECROSIS 12 0.0059
122 DRUG RESISTANCE 150 0.0058
123 DYSLIPIDAEMIA 29 0.0057
124 ALCOHOL INTOLERANCE 4 0.0056
125 ALBUMINURIA 3 0.0056
126 CATHETER REMOVAL 2 0.0056
127 LABELLED DRUG-DRUG INTERACTION ISSUE 8 0.0055
128 FAT TISSUE INCREASED 8 0.0055
129 MORNING SICKNESS 3 0.0055
130 HEPATITIS B CORE ANTIBODY POSITIVE 2 0.0053
131 HYPOMETABOLISM 2 0.0052
132 LABELLED DRUG-DRUG INTERACTION MEDICATION ERROR 46 0.0052
133 POSTPARTUM HAEMORRHAGE 7 0.0052
134 CARDIOVASCULAR SYMPTOM 2 0.0052
135 INJECTION SITE INDENTATION 11 0.0051
136 FAT NECROSIS 3 0.0049
137 NODULE 63 0.0048
138 T-LYMPHOCYTE COUNT DECREASED 3 0.0044
139 INJECTION SITE CELLULITIS 8 0.0043
140 INJECTION SITE ATROPHY 7 0.0043
141 INJECTION RELATED REACTION 7 0.0042
142 NEONATAL ASPHYXIA 3 0.0042
143 CONGENITAL HYDRONEPHROSIS 3 0.0042
144 PYELOCALIECTASIS 4 0.0042
145 OCCUPATIONAL EXPOSURE TO PRODUCT 26 0.0040
146 DRUG LEVEL DECREASED 41 0.0040
147 EXPOSURE TO COMMUNICABLE DISEASE 3 0.0040
148 PANCREATIC FAILURE 7 0.0040
149 INJECTION SITE INFECTION 13 0.0040
150 LOWER RESPIRATORY TRACT INFECTION BACTERIAL 2 0.0039
151 RETINAL TOXICITY 4 0.0039
152 KELOID SCAR 2 0.0039
153 ACQUIRED IMMUNODEFICIENCY SYNDROME 2 0.0039
154 RETINAL PIGMENTATION 3 0.0038
155 MEASLES 2 0.0037
156 MANUFACTURING PRODUCT SHIPPING ISSUE 2 0.0037
157 LARYNGEAL STENOSIS 2 0.0035
158 GRAFT COMPLICATION 2 0.0034
159 PRODUCT PREPARATION ISSUE 22 0.0034
160 GAMMA-GLUTAMYLTRANSFERASE ABNORMAL 2 0.0033
161 INJECTION SITE INDURATION 42 0.0032
162 PRODUCT ADMINISTERED AT INAPPROPRIATE SITE 59 0.0032
163 LIPOHYPERTROPHY 2 0.0032
164 LIPOATROPHY 3 0.0032
165 FACIAL ASYMMETRY 3 0.0031
166 INJECTION SITE SCAB 3 0.0031
167 ABSCESS LIMB 13 0.0030
168 INJECTION SITE INFLAMMATION 15 0.0030
169 VACCINATION FAILURE 5 0.0030
170 LIPIDS INCREASED 6 0.0030
171 HYPOGONADISM 3 0.0030
172 GENOTYPE DRUG RESISTANCE TEST POSITIVE 3 0.0029
173 CORONAVIRUS TEST POSITIVE 3 0.0029
174 POLYCYTHAEMIA 6 0.0029
175 HEPATITIS C 35 0.0029
176 HAEMATOSPERMIA 2 0.0029
177 EXPOSURE DURING PREGNANCY 176 0.0028
178 HEART DISEASE CONGENITAL 10 0.0028
179 FACIAL PARESIS 10 0.0028
180 AMNIOTIC CAVITY INFECTION 2 0.0028
181 CENTRAL OBESITY 2 0.0027
182 BK VIRUS INFECTION 9 0.0027
183 RENAL COLIC 6 0.0027
184 COMPLICATION OF PREGNANCY 2 0.0026
185 CREATINE KINASE INCREASED 2 0.0026
186 FOLATE DEFICIENCY 3 0.0026
187 MICTURITION DISORDER 9 0.0026
188 BLOOD KETONE BODY INCREASED 2 0.0026
189 MYCOPLASMA INFECTION 2 0.0026
190 HEPATITIS E 4 0.0025
191 PNEUMONIA LEGIONELLA 4 0.0025
192 HEPATITIS VIRAL 2 0.0025
193 PROSTATITIS 7 0.0023
194 BIPOLAR I DISORDER 5 0.0023
195 PRODUCT DOSE OMISSION ISSUE 670 0.0023
196 PRODUCT ADMINISTRATION ERROR 46 0.0023
197 DEPRESSIVE SYMPTOM 8 0.0023
198 MULTIPLE-DRUG RESISTANCE 7 0.0023
199 TRANSPLANT DYSFUNCTION 4 0.0022
200 BLOOD ALKALINE PHOSPHATASE ABNORMAL 2 0.0022
201 INJECTION SITE PAIN 682 0.0022
202 WRONG TECHNIQUE IN DEVICE USAGE PROCESS 103 0.0022
203 GASTRIC OPERATION 2 0.0022
204 BLOOD CHOLESTEROL ABNORMAL 10 0.0022
205 DISCHARGE 3 0.0022
206 CONGESTIVE CARDIOMYOPATHY 9 0.0022
207 POLYOMAVIRUS-ASSOCIATED NEPHROPATHY 5 0.0021
208 ANTIPSYCHOTIC DRUG LEVEL INCREASED 6 0.0021
209 INJECTION SITE SCAR 6 0.0021
210 INJECTION SITE HYPOAESTHESIA 3 0.0021
211 INJECTION SITE MASS 77 0.0021
212 TREATMENT FAILURE 172 0.0021
213 RENAL INFARCT 3 0.0021
214 WRONG PRODUCT ADMINISTERED 14 0.0021
215 ANAL CANCER 2 0.0021
216 VENOUS THROMBOSIS 8 0.0020
217 PATENT DUCTUS ARTERIOSUS 8 0.0020
218 PRODUCT STORAGE ERROR 176 0.0020
219 CENTRAL VENOUS CATHETERISATION 6 0.0020
220 ENURESIS 8 0.0020
221 MACULOPATHY 7 0.0020
222 BREAST NEOPLASM 2 0.0019
223 SELF-INJURIOUS IDEATION 8 0.0019
224 TREATMENT NONCOMPLIANCE 103 0.0019
225 ACARODERMATITIS 2 0.0018
226 IMMEDIATE POST-INJECTION REACTION 2 0.0018
227 SKIN MASS 12 0.0018
228 NEPHROPATHY TOXIC 20 0.0018
229 METABOLIC SURGERY 2 0.0018
230 ERECTILE DYSFUNCTION 45 0.0018
231 TRANSPLANT REJECTION 14 0.0017
232 DYSLEXIA 2 0.0017
233 ABSCESS 27 0.0017
234 PRE-ECLAMPSIA 8 0.0017
235 VARICELLA 4 0.0017
236 DRUG MONITORING PROCEDURE NOT PERFORMED 3 0.0017
237 HAEMATOMA MUSCLE 2 0.0017
238 MAJOR DEPRESSION 12 0.0016
239 ESSENTIAL HYPERTENSION 3 0.0016
240 SCIATICA 26 0.0016
241 GLOMERULAR FILTRATION RATE DECREASED 20 0.0016
242 ECTOPIC PREGNANCY 5 0.0016
243 HELICOBACTER GASTRITIS 2 0.0016
244 BLADDER DISCOMFORT 2 0.0016
245 IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME 8 0.0016
246 GASTRIC ULCER PERFORATION 2 0.0016
247 PATIENT DISSATISFACTION WITH TREATMENT 3 0.0016
248 INTERCEPTED PRODUCT SELECTION ERROR 2 0.0015
249 DRUG CLEARANCE DECREASED 2 0.0015
250 SKIN ODOUR ABNORMAL 6 0.0015
251 UNDERWEIGHT 3 0.0015
252 INJECTION SITE WARMTH 31 0.0015
253 CLUSTER HEADACHE 2 0.0015
254 INFARCTION 10 0.0015
255 SKIN INDURATION 3 0.0014
256 DERMATITIS EXFOLIATIVE GENERALISED 5 0.0014
257 PROCTITIS 4 0.0014
258 ALANINE AMINOTRANSFERASE ABNORMAL 3 0.0014
259 RENAL TUBULAR DISORDER 4 0.0014
260 PREMATURE LABOUR 8 0.0014
261 APPENDICECTOMY 5 0.0014
262 INCORRECT ROUTE OF PRODUCT ADMINISTRATION 24 0.0014
263 CERVICAL DYSPLASIA 3 0.0014
264 NEGATIVE THOUGHTS 4 0.0014
265 CARDIAC FIBRILLATION 2 0.0014
266 ABORTION SPONTANEOUS 54 0.0013
267 NEPHRECTOMY 2 0.0013
268 PRODUCT DISPENSING ERROR 29 0.0013
269 MARASMUS 2 0.0013
270 ASPARTATE AMINOTRANSFERASE ABNORMAL 2 0.0013
271 GENITAL HERPES 2 0.0013
272 INJECTION SITE PARAESTHESIA 2 0.0013
273 MEAN CELL VOLUME DECREASED 2 0.0013
274 PSYCHOTIC DISORDER 38 0.0013
275 PREGNANCY WITH IMPLANT CONTRACEPTIVE 6 0.0013
276 INJECTION SITE REACTION 88 0.0013
277 ESCHERICHIA BACTERAEMIA 3 0.0013
278 GASTROINTESTINAL TOXICITY 6 0.0012
279 HEPATITIS ACUTE 8 0.0012
280 BACTERIAL SEPSIS 4 0.0012
281 POLYURIA 10 0.0012
282 ASPERGILLUS INFECTION 8 0.0012
283 ACUTE PSYCHOSIS 3 0.0012
284 INTERCEPTED PRODUCT DISPENSING ERROR 2 0.0012
285 HIGH DENSITY LIPOPROTEIN DECREASED 4 0.0012
286 NEUROTOXICITY 21 0.0012
287 CONTRAINDICATED PRODUCT PRESCRIBED 2 0.0012
288 MYCOBACTERIAL INFECTION 2 0.0012
289 FOETAL GROWTH RESTRICTION 7 0.0012
290 PREGNANCY ON ORAL CONTRACEPTIVE 3 0.0011
291 TYPE I HYPERSENSITIVITY 4 0.0011
292 LIVER FUNCTION TEST INCREASED 24 0.0011
293 MYCOBACTERIUM AVIUM COMPLEX INFECTION 3 0.0011
294 WEIGHT FLUCTUATION 11 0.0011
295 MUSCULOSKELETAL PAIN 55 0.0010
296 VENTRICULAR SEPTAL DEFECT 6 0.0010
297 GAIT INABILITY 35 0.0010
298 POOR QUALITY PRODUCT ADMINISTERED 11 0.0010
299 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 184 0.0010
300 DRUG INTERACTION 160 0.0010
301 LOW BIRTH WEIGHT BABY 8 0.0010
302 ANORECTAL DISORDER 2 0.0010
303 FOETAL EXPOSURE DURING PREGNANCY 81 0.0010
304 BRAIN DEATH 3 0.0010
305 TRISMUS 5 0.0010
306 CHEST INJURY 2 0.0010
307 AORTIC DISSECTION 4 0.0010
308 INJECTION SITE SWELLING 74 0.0010
309 INJECTION SITE HYPERSENSITIVITY 3 0.0010
310 BLOOD CREATININE DECREASED 3 0.0010
311 LIVE BIRTH 8 0.0010
312 MUSCLE ATROPHY 12 0.0009
313 PRESYNCOPE 23 0.0009
314 SUBSTANCE USE DISORDER 3 0.0009
315 PULMONARY TUBERCULOSIS 4 0.0009
316 MASS 13 0.0009
317 INFECTION SUSCEPTIBILITY INCREASED 2 0.0009
318 ELECTROCARDIOGRAM T WAVE INVERSION 2 0.0009
319 PRODUCT PHYSICAL CONSISTENCY ISSUE 5 0.0009
320 RHINITIS ALLERGIC 4 0.0009
321 INJECTION SITE EXTRAVASATION 11 0.0009
322 EXPOSURE VIA SKIN CONTACT 23 0.0009
323 CHRONIC GASTRITIS 2 0.0009
324 EYELID PTOSIS 9 0.0009
325 B-CELL LYMPHOMA 3 0.0009
326 HAEMATOCRIT INCREASED 2 0.0009
327 PRODUCT PREPARATION ERROR 18 0.0009
328 INJECTION SITE PAPULE 4 0.0009
329 TACHYPHRENIA 3 0.0009
330 INTERCEPTED MEDICATION ERROR 4 0.0009
331 LICHEN PLANUS 2 0.0009
332 EYELID OEDEMA 10 0.0009
333 ACUTE FEBRILE NEUTROPHILIC DERMATOSIS 2 0.0009
334 PAPULE 6 0.0009
335 ABORTION INDUCED 8 0.0008
336 FEELING HOT 52 0.0008
337 CONJUNCTIVAL HYPERAEMIA 3 0.0008
338 INTERCEPTED PRODUCT STORAGE ERROR 3 0.0008
339 HEPATITIS CHOLESTATIC 5 0.0008
340 BLOOD IMMUNOGLOBULIN E INCREASED 2 0.0008
341 DERMAL CYST 2 0.0008
342 HYDRONEPHROSIS 6 0.0008
343 MULTIPLE INJURIES 5 0.0008
344 DRUG TOLERANCE 4 0.0008
345 HEPATITIS 20 0.0008
346 LOW DENSITY LIPOPROTEIN INCREASED 6 0.0008
347 LIPOMA 2 0.0008
348 MUSCLE RUPTURE 3 0.0008
349 HERPES SIMPLEX 5 0.0008
350 RESPIRATORY ACIDOSIS 3 0.0008
351 INJECTION SITE HAEMATOMA 11 0.0008
352 PRODUCT DISTRIBUTION ISSUE 7 0.0008
353 ATRIAL FLUTTER 6 0.0008
354 AREFLEXIA 2 0.0007
355 OVERWEIGHT 4 0.0007
356 LACTIC ACIDOSIS 24 0.0007
357 CLUMSINESS 2 0.0007
358 HYPERURICAEMIA 3 0.0007
359 DRUG LEVEL INCREASED 12 0.0007
360 EOSINOPHILIC OESOPHAGITIS 2 0.0007
361 MACULE 2 0.0007
362 AGGRESSION 36 0.0007
363 DEPRESSED MOOD 38 0.0007
364 HEPATOTOXICITY 16 0.0007
365 DIABETIC COMA 2 0.0007
366 ANGIOPATHY 4 0.0007
367 PULMONARY ALVEOLAR HAEMORRHAGE 4 0.0007
368 ATTENTION DEFICIT HYPERACTIVITY DISORDER 3 0.0007
369 THERAPY CHANGE 7 0.0007
370 LYMPHOMA 11 0.0007
371 MUSCLE FATIGUE 3 0.0007
372 CHOLECYSTITIS ACUTE 4 0.0007
373 NEOPLASM 8 0.0007
374 FINE MOTOR SKILL DYSFUNCTION 2 0.0007
375 SKIN WARM 4 0.0007
376 LUMBAR SPINAL STENOSIS 2 0.0007
377 CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR 23 0.0007
378 HYPOPHOSPHATAEMIA 5 0.0007
379 HYPERLIPIDAEMIA 8 0.0007
380 ATYPICAL PNEUMONIA 2 0.0007
381 OROPHARYNGEAL DISCOMFORT 6 0.0007
382 HIV INFECTION 2 0.0007
383 INJECTION SITE VESICLES 4 0.0007
384 CRANIOCEREBRAL INJURY 2 0.0007
385 HAEMOGLOBIN INCREASED 3 0.0007
386 FIBROSIS 2 0.0006
387 DEPRESSION 145 0.0006
388 MYALGIA 108 0.0006
389 SKIN ABRASION 3 0.0006
390 EOSINOPHILIC PNEUMONIA 2 0.0006
391 PREMATURE BABY 19 0.0006
392 HEPATIC CYTOLYSIS 8 0.0006
393 MOOD ALTERED 17 0.0006
394 CUSHINGOID 2 0.0006
395 LIVER ABSCESS 2 0.0006
396 INCORRECT DISPOSAL OF PRODUCT 2 0.0006
397 PHARYNGEAL SWELLING 6 0.0006
398 IMMUNOSUPPRESSANT DRUG LEVEL INCREASED 2 0.0006
399 SYNCOPE 60 0.0006
400 INFLUENZA LIKE ILLNESS 49 0.0006
401 EMPHYSEMA 6 0.0006
402 DISCOMFORT 36 0.0006
403 MATERNAL EXPOSURE BEFORE PREGNANCY 4 0.0006
404 PERIPHERAL COLDNESS 8 0.0006
405 ANAPHYLACTIC REACTION 32 0.0006
406 ORAL DISCOMFORT 8 0.0006
407 HYPERTRANSAMINASAEMIA 4 0.0006
408 MUSCLE CONTRACTIONS INVOLUNTARY 2 0.0006
409 FOOD POISONING 3 0.0006
410 PANIC REACTION 4 0.0006
411 CUTANEOUS VASCULITIS 2 0.0005
412 ASTHMATIC CRISIS 2 0.0005
413 ABNORMAL DREAMS 15 0.0005
414 PYREXIA 186 0.0005
415 TYPE 2 DIABETES MELLITUS 18 0.0005
416 ECONOMIC PROBLEM 8 0.0005
417 NIGHT SWEATS 17 0.0005
418 ACIDOSIS 4 0.0005
419 PAIN 321 0.0005
420 CLAVICLE FRACTURE 2 0.0005
421 HERPES VIRUS INFECTION 3 0.0005
422 CARDIOPULMONARY FAILURE 2 0.0005
423 SPLENOMEGALY 6 0.0005
424 FEELING OF BODY TEMPERATURE CHANGE 3 0.0005
425 SKIN LESION 14 0.0005
426 GLUCOSE TOLERANCE IMPAIRED 3 0.0005
427 PNEUMOCYSTIS JIROVECII PNEUMONIA 5 0.0005
428 SENSORY LOSS 4 0.0005
429 TOXIC SKIN ERUPTION 5 0.0005
430 NEURALGIA 12 0.0005
431 FLUSHING 50 0.0005
432 HELICOBACTER INFECTION 5 0.0005
433 CONCOMITANT DISEASE AGGRAVATED 3 0.0005
434 ANAPHYLACTOID REACTION 2 0.0005
435 PIGMENTATION DISORDER 3 0.0005
436 PARAESTHESIA ORAL 7 0.0005
437 PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY 4 0.0005
438 CHOLANGITIS 3 0.0005
439 OLIGURIA 3 0.0005
440 HYPERBILIRUBINAEMIA 5 0.0005
441 MENTAL DISORDER 21 0.0005
442 SLEEP DISORDER 34 0.0005
443 VENTRICULAR EXTRASYSTOLES 5 0.0005
444 EOSINOPHIL COUNT INCREASED 4 0.0005
445 NEUROPATHY PERIPHERAL 45 0.0005
446 ELECTROCARDIOGRAM QT PROLONGED 17 0.0005
447 SUDDEN DEATH 5 0.0005
448 HYPERPYREXIA 2 0.0005
449 DIABETES MELLITUS 36 0.0005
450 LUNG NEOPLASM 2 0.0005
451 SCAR 8 0.0005
452 MYOPATHY 4 0.0005
453 ILL-DEFINED DISORDER 28 0.0005
454 MONOPLEGIA 2 0.0005
455 BIPOLAR DISORDER 5 0.0005
456 MOBILITY DECREASED 33 0.0005
457 ANHEDONIA 12 0.0005
458 EYE DISORDER 15 0.0005
459 CORONAVIRUS INFECTION 3 0.0005
460 ARTERIOSCLEROSIS CORONARY ARTERY 3 0.0005
461 RASH MACULO-PAPULAR 10 0.0004
462 BASAL CELL CARCINOMA 7 0.0004
463 POST-TRAUMATIC STRESS DISORDER 3 0.0004
464 SUICIDE ATTEMPT 27 0.0004
465 HEAVY MENSTRUAL BLEEDING 4 0.0004
466 PRODUCT USE ISSUE 83 0.0004
467 ALANINE AMINOTRANSFERASE INCREASED 27 0.0004
468 PREMATURE DELIVERY 7 0.0004
469 ECCHYMOSIS 3 0.0004
470 LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES 21 0.0004
471 INJECTION SITE ERYTHEMA 54 0.0004
472 CHILLS 51 0.0004
473 INCORRECT DOSE ADMINISTERED 99 0.0004
474 NIGHTMARE 15 0.0004
475 IRON DEFICIENCY ANAEMIA 4 0.0004
476 NEPHROGENIC ANAEMIA 2 0.0004
477 AUTOIMMUNE HEPATITIS 3 0.0004
478 FEELING OF DESPAIR 2 0.0004
479 BLOOD CREATININE INCREASED 28 0.0004
480 APPENDICITIS 4 0.0004
481 FLANK PAIN 4 0.0004
482 UNDERDOSE 31 0.0004
483 HAEMATOMA 11 0.0004
484 GYNAECOMASTIA 13 0.0004
485 NEUTROPENIC SEPSIS 3 0.0004
486 LEUKOPENIA 21 0.0004
487 GESTATIONAL DIABETES 2 0.0004
488 HYPERHIDROSIS 54 0.0004
489 POLYNEUROPATHY 5 0.0004
490 SUICIDAL IDEATION 38 0.0004
491 SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION 7 0.0004
492 INCORRECT DOSAGE ADMINISTERED 2 0.0004
493 INABILITY TO AFFORD MEDICATION 4 0.0004
494 EOSINOPHILIA 7 0.0004
495 CONDITION AGGRAVATED 121 0.0004
496 CORONARY ARTERY STENOSIS 2 0.0004
497 COLD SWEAT 7 0.0004
498 DYSPHORIA 2 0.0004
499 DISSOCIATION 3 0.0004
500 LIP SWELLING 13 0.0004
501 OSTEOPOROSIS 16 0.0004
502 RASH PRURITIC 21 0.0004
503 BENIGN PROSTATIC HYPERPLASIA 2 0.0004
504 APHTHOUS ULCER 3 0.0004
505 FOETAL DEATH 2 0.0004
506 NERVOUS SYSTEM DISORDER 12 0.0004
507 TENDERNESS 4 0.0004
508 AFFECTIVE DISORDER 3 0.0004
509 PRODUCT USE COMPLAINT 6 0.0004
510 ORAL CANDIDIASIS 5 0.0004
511 THERAPEUTIC RESPONSE UNEXPECTED 17 0.0004
512 HEPATIC CIRRHOSIS 7 0.0004
513 ACUTE KIDNEY INJURY 57 0.0004
514 MUSCLE DISORDER 3 0.0004
515 BACK PAIN 86 0.0004
516 INCORRECT PRODUCT ADMINISTRATION DURATION 8 0.0004
517 HYPERAESTHESIA 3 0.0004
518 GASTROINTESTINAL PAIN 4 0.0004
519 DRUG LEVEL BELOW THERAPEUTIC 2 0.0004
520 ACUTE CORONARY SYNDROME 3 0.0004
521 TRANSAMINASES INCREASED 8 0.0004
522 HYPERTENSIVE CRISIS 4 0.0004
523 INTRACRANIAL PRESSURE INCREASED 2 0.0004
524 WOUND 10 0.0004
525 CELLULITIS 18 0.0004
526 PANCREATITIS ACUTE 8 0.0004
527 FISTULA 4 0.0004
528 HEPATIC ENZYME INCREASED 24 0.0004
529 BRONCHOSPASM 5 0.0004
530 OFF LABEL USE 306 0.0003
531 SKIN HYPERPIGMENTATION 3 0.0003
532 ANGINA PECTORIS 10 0.0003
533 NEPHROLITHIASIS 16 0.0003
534 ANXIETY 99 0.0003
535 MOUTH SWELLING 2 0.0003
536 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 70 0.0003
537 INJURY ASSOCIATED WITH DEVICE 7 0.0003
538 VASCULITIS 4 0.0003
539 INJECTION SITE PRURITUS 23 0.0003
540 URINE OUTPUT DECREASED 3 0.0003
541 IMMUNOSUPPRESSION 3 0.0003
542 PRODUCT COMMUNICATION ISSUE 3 0.0003
543 OESOPHAGEAL CARCINOMA 10 0.0003
544 OCULAR HYPERAEMIA 16 0.0003
545 FACIAL PAIN 3 0.0003
546 PRODUCT PRESCRIBING ERROR 8 0.0003
547 MYOSITIS 3 0.0003
548 ANAL INCONTINENCE 3 0.0003
549 CHEST DISCOMFORT 34 0.0003
550 TOOTHACHE 6 0.0003
551 LUPUS-LIKE SYNDROME 3 0.0003
552 OPTIC NEURITIS 3 0.0003
553 HYPERGLYCAEMIA 12 0.0003
554 EPILEPSY 10 0.0003
555 HEPATIC STEATOSIS 6 0.0003
556 RENAL IMPAIRMENT 27 0.0003
557 EXTRA DOSE ADMINISTERED 13 0.0003
558 CLOSTRIDIUM DIFFICILE INFECTION 7 0.0003
559 ASPARTATE AMINOTRANSFERASE INCREASED 17 0.0003
560 BRAIN FOG 5 0.0003
561 WEIGHT DECREASED 89 0.0003
562 TACHYCARDIA 28 0.0003
563 CARDIOVASCULAR DISORDER 8 0.0003
564 OBESITY 5 0.0003
565 GAIT DISTURBANCE 60 0.0003
566 BLOOD CREATINE PHOSPHOKINASE INCREASED 9 0.0003
567 ANAPHYLACTIC SHOCK 8 0.0003
568 MUSCLE TIGHTNESS 5 0.0003
569 HYPERPROLACTINAEMIA 2 0.0003
570 VITAMIN D DEFICIENCY 3 0.0003
571 BEDRIDDEN 4 0.0003
572 MANIA 5 0.0003
573 DYSGRAPHIA 2 0.0003
574 PHOTOSENSITIVITY REACTION 5 0.0003
575 SKIN DISORDER 10 0.0003
576 QUALITY OF LIFE DECREASED 4 0.0003
577 CONTRAINDICATED PRODUCT ADMINISTERED 9 0.0003
578 OEDEMA 16 0.0003
579 TACHYPNOEA 4 0.0003
580 PALLOR 8 0.0003
581 ACUTE HEPATIC FAILURE 4 0.0003
582 BLOOD TESTOSTERONE DECREASED 2 0.0003
583 ILLNESS 30 0.0003
584 MUSCULOSKELETAL DISCOMFORT 5 0.0003
585 JOINT EFFUSION 2 0.0003
586 ADVERSE DRUG REACTION 26 0.0003
587 UNINTENDED PREGNANCY 3 0.0003
588 DRUG-INDUCED LIVER INJURY 9 0.0003
589 DEFAECATION URGENCY 2 0.0003
590 SEASONAL ALLERGY 4 0.0003
591 LYMPHADENOPATHY 10 0.0003
592 HAND FRACTURE 2 0.0003
593 HEPATOCELLULAR INJURY 4 0.0003
594 FEAR OF INJECTION 2 0.0003
595 PARALYSIS 4 0.0003
596 SKIN LACERATION 3 0.0003
597 STAPHYLOCOCCAL INFECTION 9 0.0003
598 MUSCULAR WEAKNESS 31 0.0003
599 ANGIOEDEMA 12 0.0003
600 SKIN ULCER 7 0.0003
601 NERVE INJURY 3 0.0003
602 MALNUTRITION 3 0.0003
603 INSOMNIA 71 0.0003
604 HYPERTENSION 56 0.0003
605 OSTEOPENIA 4 0.0003
606 DYSPHAGIA 25 0.0003
607 GASTRIC ULCER 5 0.0003
608 HEPATOCELLULAR CARCINOMA 2 0.0003
609 ROAD TRAFFIC ACCIDENT 11 0.0003
610 ACCIDENTAL EXPOSURE TO PRODUCT 27 0.0003
611 RASH 114 0.0003
612 BOWEL MOVEMENT IRREGULARITY 2 0.0003
613 INTERCEPTED PRODUCT ADMINISTRATION ERROR 2 0.0003
614 JAUNDICE 7 0.0003
615 GLAUCOMA 5 0.0003
616 WEIGHT INCREASED 58 0.0003
617 BURNING SENSATION 18 0.0003
618 URTICARIA 43 0.0003
619 HAEMORRHOIDS 5 0.0003
620 CHOKING 5 0.0003
621 HAEMORRHAGIC STROKE 2 0.0003
622 PARAESTHESIA 40 0.0003
623 FURUNCLE 2 0.0003
624 MENTAL STATUS CHANGES 7 0.0003
625 BLOOD PRESSURE ABNORMAL 5 0.0003
626 GINGIVAL PAIN 2 0.0003
627 MOOD SWINGS 8 0.0003
628 MALAISE 109 0.0002
629 LIVER DISORDER 11 0.0002
630 PRODUCT DOSE OMISSION IN ERROR 7 0.0002
631 MULTIPLE ORGAN DYSFUNCTION SYNDROME 7 0.0002
632 CYTOPENIA 3 0.0002
633 ASPHYXIA 2 0.0002
634 LIVER INJURY 6 0.0002
635 SPINAL OPERATION 3 0.0002
636 PRODUCT USE IN UNAPPROVED INDICATION 60 0.0002
637 MENSTRUAL DISORDER 2 0.0002
638 HEPATIC FUNCTION ABNORMAL 9 0.0002
639 INJECTION SITE DISCOLOURATION 3 0.0002
640 MUSCLE SPASMS 44 0.0002
641 ATRIAL SEPTAL DEFECT 2 0.0002
642 ADVERSE EVENT 22 0.0002
643 DERMATITIS ALLERGIC 3 0.0002
644 DRUG INTOLERANCE 23 0.0002
645 ARTHRALGIA 99 0.0002
646 PERICARDITIS 4 0.0002
647 ACUTE MYOCARDIAL INFARCTION 7 0.0002
648 URINARY INCONTINENCE 7 0.0002
649 SWELLING 22 0.0002
650 PAIN IN EXTREMITY 69 0.0002
651 DYSPEPSIA 23 0.0002
652 THERAPY CESSATION 12 0.0002
653 DIZZINESS 116 0.0002
654 POOR QUALITY SLEEP 5 0.0002
655 PULMONARY EMBOLISM 22 0.0002
656 DISEASE RECURRENCE 11 0.0002
657 PLATELET COUNT INCREASED 3 0.0002
658 JOINT STIFFNESS 6 0.0002
659 INJECTION SITE RASH 7 0.0002
660 GASTRITIS 6 0.0002
661 COVID-19 40 0.0002
662 GROIN PAIN 2 0.0002
663 BLOOD TRIGLYCERIDES INCREASED 4 0.0002
664 LETHARGY 13 0.0002
665 INJECTION SITE HAEMORRHAGE 18 0.0002
666 ISCHAEMIC STROKE 4 0.0002
667 THIRST 4 0.0002
668 ERYTHEMA 46 0.0002
669 HAEMOLYTIC ANAEMIA 2 0.0002
670 RASH PAPULAR 5 0.0002
671 LOSS OF LIBIDO 2 0.0002
672 BLOOD BILIRUBIN INCREASED 6 0.0002
673 HEADACHE 139 0.0002
674 PRODUCT TASTE ABNORMAL 3 0.0002
675 UVEITIS 3 0.0002
676 LEUKOCYTOSIS 4 0.0002
677 FATIGUE 172 0.0002
678 HYPERSENSITIVITY 41 0.0002
679 PELVIC PAIN 4 0.0002
680 END STAGE RENAL DISEASE 4 0.0002
681 RESPIRATORY DISTRESS 6 0.0002
682 INCREASED TENDENCY TO BRUISE 2 0.0002
683 IRRITABILITY 13 0.0002
684 SWELLING FACE 14 0.0002
685 NECK PAIN 12 0.0002
686 RENAL DISORDER 10 0.0002
687 DIARRHOEA HAEMORRHAGIC 2 0.0002
688 TUBULOINTERSTITIAL NEPHRITIS 4 0.0002
689 OSTEONECROSIS 7 0.0002
690 SKIN REACTION 3 0.0002
691 ARTERIOSCLEROSIS 2 0.0002
692 ABDOMINAL PAIN 49 0.0002
693 CHRONIC KIDNEY DISEASE 16 0.0002
694 HYPERSOMNIA 6 0.0002
695 HYPERTHYROIDISM 3 0.0002
696 HYPERCHOLESTEROLAEMIA 2 0.0002
697 GASTROENTERITIS 3 0.0002
698 SOMNOLENCE 41 0.0002
699 ENCEPHALOPATHY 5 0.0002
700 HOSPICE CARE 2 0.0002
701 PULMONARY MASS 3 0.0002
702 EXTRAPYRAMIDAL DISORDER 5 0.0002
703 HYPOAESTHESIA 30 0.0002
704 HYPOTONIA 2 0.0002
705 RASH MACULAR 7 0.0002
706 BRAIN INJURY 2 0.0002
707 HEPATIC FAILURE 6 0.0002
708 APHASIA 6 0.0002
709 LACRIMATION INCREASED 6 0.0002
710 MOTOR DYSFUNCTION 2 0.0002
711 TOXICITY TO VARIOUS AGENTS 33 0.0002
712 EAR DISCOMFORT 2 0.0002
713 RIB FRACTURE 4 0.0002
714 LIMB DISCOMFORT 6 0.0002
715 DELUSION 3 0.0002
716 TOOTH LOSS 4 0.0002
717 SWOLLEN TONGUE 6 0.0002
718 MOUTH ULCERATION 4 0.0002
719 GASTROINTESTINAL DISORDER 17 0.0002
720 VOMITING 89 0.0002
721 MOVEMENT DISORDER 6 0.0002
722 RHINORRHOEA 12 0.0002
723 DECREASED ACTIVITY 2 0.0002
724 THROAT TIGHTNESS 5 0.0002
725 BLOOD POTASSIUM INCREASED 3 0.0002
726 OROPHARYNGEAL PAIN 17 0.0002
727 ASPIRATION 2 0.0002
728 DYSPNOEA 103 0.0002
729 VENTRICULAR TACHYCARDIA 3 0.0002
730 LOSS OF CONSCIOUSNESS 23 0.0002
731 MATERNAL EXPOSURE DURING PREGNANCY 16 0.0002
732 PANCYTOPENIA 10 0.0002
733 DIARRHOEA 115 0.0002
734 THERAPY NON-RESPONDER 8 0.0002
735 FACE OEDEMA 3 0.0002
736 FLUID RETENTION 9 0.0002
737 DISORIENTATION 7 0.0002
738 CHOLECYSTECTOMY 2 0.0002
739 MYOCARDITIS 2 0.0002
740 HYPOTENSION 35 0.0002
741 PRURITUS 67 0.0002
742 GASTRIC HAEMORRHAGE 2 0.0002
743 NAUSEA 137 0.0002
744 CHEST PAIN 32 0.0002
745 SYRINGE ISSUE 3 0.0002
746 PANCREATITIS 9 0.0002
747 ASCITES 5 0.0002
748 HEAD DISCOMFORT 3 0.0002
749 DIABETES MELLITUS INADEQUATE CONTROL 3 0.0002
750 NEUTROPENIA 23 0.0002
751 RHABDOMYOLYSIS 7 0.0002
752 GOUT 3 0.0002
753 ABDOMINAL DISCOMFORT 28 0.0002
754 BLOOD PRESSURE DECREASED 11 0.0002
755 CRYING 6 0.0002
756 RESPIRATORY FAILURE 12 0.0002
757 VERTIGO 10 0.0002
758 HOSPITALISATION 25 0.0002
759 MEDICATION ERROR 9 0.0002
760 DYSGEUSIA 12 0.0002
761 GASTROOESOPHAGEAL REFLUX DISEASE 13 0.0002
762 AGRANULOCYTOSIS 3 0.0002
763 CYST 2 0.0002
764 ILEUS 2 0.0002
765 MYOCARDIAL INFARCTION 28 0.0002
766 MUSCULOSKELETAL STIFFNESS 14 0.0002
767 HOT FLUSH 12 0.0002
768 GLYCOSYLATED HAEMOGLOBIN INCREASED 4 0.0002
769 COLITIS 6 0.0002
770 ACNE 12 0.0002
771 FOOT FRACTURE 3 0.0002
772 ABDOMINAL PAIN LOWER 4 0.0002
773 MUSCULOSKELETAL DISORDER 3 0.0002
774 DEHYDRATION 21 0.0002
775 INJECTION SITE IRRITATION 2 0.0002
776 HERPES ZOSTER 9 0.0002
777 HYPOTHYROIDISM 5 0.0002
778 THROAT IRRITATION 7 0.0002
779 COMPLETED SUICIDE 13 0.0002
780 ACUTE RESPIRATORY FAILURE 3 0.0002
781 SKIN EXFOLIATION 13 0.0002
782 DIPLOPIA 4 0.0002
783 PALPITATIONS 18 0.0002
784 ORAL HERPES 3 0.0002
785 SURGERY 9 0.0002
786 IMMUNE SYSTEM DISORDER 2 0.0002
787 ADVERSE REACTION 2 0.0002
788 FEELING ABNORMAL 36 0.0002
789 BLOOD CHOLESTEROL INCREASED 7 0.0002
790 COUGH 42 0.0001
791 SPINAL FRACTURE 3 0.0001
792 CARDIAC FAILURE 12 0.0001
793 MENSTRUATION IRREGULAR 4 0.0001
794 PROSTATE CANCER 12 0.0001
795 EYE PRURITUS 5 0.0001
796 PRODUCT PHYSICAL ISSUE 3 0.0001
797 STOMATITIS 9 0.0001
798 ANGER 5 0.0001
799 LIMB INJURY 4 0.0001
800 BODY TEMPERATURE INCREASED 3 0.0001
801 PRODUCTIVE COUGH 7 0.0001
802 LUNG NEOPLASM MALIGNANT 6 0.0001
803 ABDOMINAL DISTENSION 15 0.0001
804 ALOPECIA 28 0.0001
805 LYMPHOPENIA 2 0.0001
806 DEEP VEIN THROMBOSIS 9 0.0001
807 PANIC ATTACK 5 0.0001
808 APATHY 2 0.0001
809 CARDIAC FAILURE CONGESTIVE 11 0.0001
810 RESTLESSNESS 5 0.0001
811 ASTHENIA 51 0.0001
812 LABORATORY TEST ABNORMAL 4 0.0001
813 STEVENS-JOHNSON SYNDROME 3 0.0001
814 COLON CANCER 2 0.0001
815 HAEMORRHAGE INTRACRANIAL 2 0.0001
816 SNEEZING 3 0.0001
817 DECREASED APPETITE 31 0.0001
818 CHROMATURIA 3 0.0001
819 DYSARTHRIA 5 0.0001
820 HEART RATE IRREGULAR 3 0.0001
821 CEREBROVASCULAR ACCIDENT 22 0.0001
822 DISTURBANCE IN ATTENTION 7 0.0001
823 PNEUMONIA 42 0.0001
824 MUSCULOSKELETAL CHEST PAIN 2 0.0001
825 VISUAL IMPAIRMENT 16 0.0001
826 COGNITIVE DISORDER 6 0.0001
827 MENINGIOMA 2 0.0001
828 HAEMATOCHEZIA 7 0.0001
829 ABNORMAL BEHAVIOUR 5 0.0001
830 ARTHROPATHY 7 0.0001
831 THROMBOCYTOPENIA 14 0.0001
832 DIABETIC KETOACIDOSIS 3 0.0001
833 CONTUSION 12 0.0001
834 INFECTION 18 0.0001
835 BLOOD PRESSURE INCREASED 19 0.0001
836 EYE PAIN 7 0.0001
837 EMOTIONAL DISTRESS 15 0.0001
838 DRY MOUTH 10 0.0001
839 BACK DISORDER 2 0.0001
840 GENERALISED TONIC-CLONIC SEIZURE 2 0.0001
841 BLOOD ALKALINE PHOSPHATASE INCREASED 3 0.0001
842 CYTOMEGALOVIRUS INFECTION 2 0.0001
843 PNEUMONIA ASPIRATION 3 0.0001
844 FUNGAL INFECTION 4 0.0001
845 DRY SKIN 16 0.0001
846 HALLUCINATION 9 0.0001
847 TRANSIENT ISCHAEMIC ATTACK 4 0.0001
848 CIRCULATORY COLLAPSE 2 0.0001
849 DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 3 0.0001
850 MULTI-ORGAN FAILURE 2 0.0001
851 HAEMORRHAGE 12 0.0001
852 INCORRECT DOSE ADMINISTERED BY DEVICE 3 0.0001
853 RENAL FAILURE 15 0.0001
854 SEIZURE 13 0.0001
855 GALLBLADDER DISORDER 2 0.0001
856 GASTROENTERITIS VIRAL 2 0.0001
857 WHITE BLOOD CELL COUNT DECREASED 12 0.0001
858 ANAEMIA 21 0.0001
859 SKIN DISCOLOURATION 5 0.0001
860 DYSURIA 4 0.0001
861 BLOOD GLUCOSE ABNORMAL 2 0.0001
862 CONJUNCTIVITIS 2 0.0001
863 FEELING COLD 3 0.0001
864 HAEMOPTYSIS 3 0.0001
865 EYE SWELLING 4 0.0001
866 BACTERIAL INFECTION 2 0.0001
867 MIDDLE INSOMNIA 2 0.0001
868 HYPONATRAEMIA 6 0.0001
869 FRACTURE 2 0.0001
870 DEATH 91 0.0001
871 FEBRILE NEUTROPENIA 7 0.0001
872 FEELING JITTERY 2 0.0001
873 NEOPLASM MALIGNANT 7 0.0001
874 RASH ERYTHEMATOUS 5 0.0001
875 PANCREATIC CARCINOMA 3 0.0001
876 HERNIA 2 0.0001
877 ERUCTATION 2 0.0001
878 LIVER FUNCTION TEST ABNORMAL 3 0.0001
879 DYSSTASIA 3 0.0001
880 TREMOR 17 0.0001
881 RENAL INJURY 3 0.0001
882 DRY EYE 5 0.0001
883 FALL 33 0.0001
884 INTENTIONAL SELF-INJURY 2 0.0001
885 BONE MARROW FAILURE 2 0.0001
886 NASOPHARYNGITIS 18 0.0001
887 SINUSITIS 10 0.0001
888 EMOTIONAL DISORDER 3 0.0001
889 ABDOMINAL PAIN UPPER 20 0.0001
890 BONE DENSITY DECREASED 3 0.0001
891 SPEECH DISORDER 5 0.0001
892 AGITATION 7 0.0001
893 HEAD INJURY 3 0.0001
894 BRADYCARDIA 5 0.0001
895 JOINT INJURY 2 0.0001
896 IMPAIRED WORK ABILITY 2 0.0001
897 RECTAL HAEMORRHAGE 4 0.0001
898 FAECES DISCOLOURED 2 0.0001
899 INTENTIONAL PRODUCT MISUSE 8 0.0001
900 PERIPHERAL SWELLING 14 0.0001
901 INFLUENZA 10 0.0001
902 OXYGEN SATURATION DECREASED 5 0.0001
903 DRUG INEFFECTIVE 117 0.0001
904 DEVICE USE ERROR 3 0.0001
905 HYPERKALAEMIA 3 0.0001
906 BONE PAIN 5 0.0001
907 HYPOXIA 3 0.0001
908 NASAL CONGESTION 5 0.0001
909 WHEEZING 5 0.0001
910 COMA 4 0.0001
911 BLOOD GLUCOSE DECREASED 4 0.0001
912 ACCIDENTAL OVERDOSE 3 0.0001
913 INJECTION SITE URTICARIA 2 0.0001
914 VISION BLURRED 11 0.0001
915 INFLAMMATION 4 0.0001
916 NERVOUSNESS 4 0.0001
917 DEAFNESS 2 0.0001
918 ARTHRITIS 6 0.0001
919 URINARY TRACT INFECTION 13 0.0001
920 CARDIAC DISORDER 7 0.0001
921 NEUTROPHIL COUNT DECREASED 3 0.0001
922 MIGRAINE 7 0.0001
923 DRUG ABUSE 6 0.0001
924 POLLAKIURIA 3 0.0001
925 CARDIO-RESPIRATORY ARREST 3 0.0001
926 ASTHMA 8 0.0001
927 INTENTIONAL DOSE OMISSION 2 0.0001
928 GENERAL PHYSICAL HEALTH DETERIORATION 8 0.0001
929 SEPTIC SHOCK 3 0.0001
930 HAEMOGLOBIN DECREASED 7 0.0001
931 BLOOD POTASSIUM DECREASED 2 0.0001
932 LOWER RESPIRATORY TRACT INFECTION 3 0.0001
933 PLATELET COUNT DECREASED 7 0.0001
934 TINNITUS 3 0.0001
935 UPPER RESPIRATORY TRACT INFECTION 3 0.0001
936 BREAST CANCER 6 0.0001
937 ARRHYTHMIA 3 0.0001
938 METABOLIC ACIDOSIS 2 0.0001
939 HIP FRACTURE 2 0.0001
940 AMNESIA 4 0.0001
941 IMPAIRED HEALING 2 0.0001
942 DEVICE DIFFICULT TO USE 4 0.0001
943 INFUSION RELATED REACTION 4 0.0001
944 EXPIRED PRODUCT ADMINISTERED 2 0.0001
945 HAEMATURIA 2 0.0001
946 BLOOD GLUCOSE INCREASED 11 0.0001
947 MEMORY IMPAIRMENT 8 0.0001
948 OEDEMA PERIPHERAL 7 0.0001
949 ECZEMA 3 0.0001
950 INTENTIONAL PRODUCT USE ISSUE 5 0.0001
951 MYELOSUPPRESSION 2 0.0001
952 CONSTIPATION 12 0.0001
953 DYSPNOEA EXERTIONAL 2 0.0001
954 INTESTINAL OBSTRUCTION 2 0.0001
955 FLATULENCE 3 0.0001
956 EYE IRRITATION 3 0.0001
957 OVERDOSE 11 0.0001
958 HEART RATE INCREASED 5 0.0001
959 CATARACT 3 0.0001
960 INJECTION SITE BRUISING 4 0.0001
961 THROMBOSIS 4 0.0000
962 NO ADVERSE EVENT 9 0.0000
963 CONFUSIONAL STATE 8 0.0000
964 DYSKINESIA 2 0.0000
965 GASTROINTESTINAL HAEMORRHAGE 4 0.0000
966 HYPOACUSIS 2 0.0000
967 SEPSIS 5 0.0000
968 THERAPY INTERRUPTED 3 0.0000
969 SKIN BURNING SENSATION 3 0.0000
970 INTERSTITIAL LUNG DISEASE 2 0.0000
971 HYPOGLYCAEMIA 2 0.0000
972 LUNG DISORDER 2 0.0000
973 BRONCHITIS 3 0.0000
974 EPISTAXIS 3 0.0000
975 CHRONIC OBSTRUCTIVE PULMONARY DISEASE 2 0.0000
976 DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 2 0.0000
977 BLISTER 2 0.0000
978 DYSPHONIA 2 0.0000
979 JOINT SWELLING 4 0.0000
980 INTENTIONAL OVERDOSE 2 0.0000
981 PRODUCT QUALITY ISSUE 4 0.0000
982 MALIGNANT NEOPLASM PROGRESSION 3 0.0000
983 INJURY 2 0.0000
984 RHEUMATOID ARTHRITIS 3 0.0000
985 DISEASE PROGRESSION 3 0.0000
986 BALANCE DISORDER 2 0.0000
987 PSORIASIS 3 0.0000